Versant Venture Capital VI, L.P.'s Net Worth

$233 Million

Who is Versant Venture Capital VI, L.P.?

Versant Venture Capital VI, L.P. has an estimated net worth of $233 Million. This is based on reported shares across multiple companies, which include LENZ Therapeutics, Inc., Repare Therapeutics Inc., Monte Rosa Therapeutics, Inc., Century Therapeutics, Inc., Oyster Point Pharma, Inc., Akero Therapeutics, Inc., Aligos Therapeutics, Inc., Tempest Therapeutics, Inc., Pandion Therapeutics Holdco LLC, Passage BIO, Inc., Black Diamond Therapeutics, Inc., and Contineum Therapeutics, Inc..

SEC CIK

Versant Venture Capital VI, L.P.'s CIK is 0001687880

Past Insider Trading and Trends

2020 was Versant Venture Capital VI, L.P.'s most active year for acquiring shares with 10 total transactions. Versant Venture Capital VI, L.P.'s most active month to acquire stocks was the month of May. 2020 was Versant Venture Capital VI, L.P.'s most active year for disposing of shares, totalling 48 transactions. Versant Venture Capital VI, L.P.'s most active month to dispose stocks was the month of October. 2020 saw Versant Venture Capital VI, L.P. paying a total of $7,525,558.00 for 16,110,648 shares, this is the most they've acquired in one year. In 2019 Versant Venture Capital VI, L.P. cashed out on 14,663,947 shares for a total of $20,081,962.66, their largest year based on trade value.